MapLight Therapeutics
MPLT----
MapLight Therapeutics (MPLT)
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. Th...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
MapLight Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$43.2322.71%
Forecast & RatingStrong buy
14analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 20 at 05:03 AM
Maplight Therapeutics Chief Discovery Officer Anatol Kreitzer disposes of USD 1.34 million in common shares
- TradingView · Jul 17 at 08:50 PM
MapLight Therapeutics Insiders Sold Shares Worth Over $6.7M
- PUBT · Jul 17 at 08:44 PM
Maplight Therapeutics CMO Erin Pennock Foff sells USD 1.99 million in common shares
- Tip Ranks · Jul 14 at 03:05 PM
Analyst Reiterates Buy on MapLight Therapeutics, Maintains $45 Price Target Amid Optimism for ML-007C-MA
- rttnews · Jul 10 at 07:21 AM
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT
- Tip Ranks · Jul 2 at 10:15 AM
Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout
